Filing Details

Accession Number:
0001209191-21-050719
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-10 20:00:31
Reporting Period:
2021-08-06
Accepted Time:
2021-08-10 20:00:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1570392 John Michael Tomsicek C/O Crispr Therapeutics, Inc.
610 Main Street
Cambridge MA 02139
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2021-08-06 25,000 $17.75 26,891 No 4 M Direct
Common Shares Disposition 2021-08-06 19,011 $138.22 7,880 No 4 S Direct
Common Shares Disposition 2021-08-06 5,989 $139.46 1,891 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2021-03-11 25,000 $0.00 25,000 $17.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
131,000 2027-11-21 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  4. This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.